Starpharma – DEP® docetaxel positive phase 1 results; phase 2 commences
DEP® docetaxel phase 1 trial successfully completed with phase 2 to commence immediately DEP® docetaxel patients had no reports of neutropenia, a life-threatening toxicity seen in virtually all patients treated with conventional docetaxel formulations (e.g. Taxotere®) Encouraging signs of efficacy observed…
Sienna Diagnostics: Exclusive Distributor Appointed for Denmark and Sweden
Melbourne, Australia, 25 September 2017: Sienna Cancer Diagnostics, a commercial stage, medical technology company focussed on the development and commercialisation of innovative cancer-related tests, is pleased to announce the appointment of Axlab A/S as its exclusive distribution partner…
Penthrox is recommended for use in all UK ambulances
Medical Developments International Ltd (ASX: MVP) is delighted to advise the Joint Royal Colleges Ambulance Liaison Committee (JRCALC) has issued its new pain management clinical practice guidelines for UK ambulance services teams. The JRCALC guidelines now recommend the…
U.S. Patent Granted for Cynata Cymerus™ Technology
Australian stem cell and regenerative medicine company, Cynata Therapeutics Limited (ASX: CYP), is pleased to announce that the U.S. Patent and Trademark Office (USPTO) has granted a patent covering aspects of Cynata’s proprietary Cymerus™ mesenchymal stem cell technology.…
St Vincent’s Hospital Commences Global First APAS® In Situ Automated Evaluation
Australian developed advanced pathology instrument reading and interpreting plates for faster diagnosis of infectious diseases Centre of excellence laboratory to test automation efficiency in a busy real-life setting Adelaide, Australia, 27 September 2017: Australian medical technology…
Hydrix & Panorama
Today it was announced that Panorama Synergy Limited (ASX: PSY) has entered into an agreement to fully acquire Hydrix through an asset purchase agreement. This is an exciting development for both companies with the Merged Group at the…
Discovery Award to support new test for sepsis
Burnet Institute’s Global Health Diagnostics Laboratory has been awarded a prestigious Longitude Prize Discovery Award to facilitate the development of a laboratory-based sepsis assay into a point-of-care test. The award will also support the Laboratory’s bid for a…
CSL Completes Transaction to Acquire a Majority Stake in Chinese Plasma Fractionator
CSL Limited (ASX:CSL; USOTC:CSLLY) today announced that it has closed a joint venture transaction with Humanwell Healthcare Group Co. Ltd. (Humanwell; Shanghai exchange: 600079) to acquire a majority stake in plasma-derived therapies manufacturer Wuhan Zhong Yuan Rui De Biological…
Global Connections Fund Bridging Grant Awardees 2017
The Global Connections Fund is an initiative of the Australian Government’s National Innovation and Science Agenda (NISA) funded by the Department of Industry, Innovation and Science. You can see Bridging Grant Awardees here
Positive Data from Cynata MSCs in Second Preclinical Asthma Study
Positive Data from Cynata MSCs in Second Preclinical Asthma Study • Clear efficacy data for Cynata’s proprietary Cymerus™ MSCs in second preclinical study in a clinically-relevant model of asthma • Cymerus MSCs caused significantly greater reduction of airway…
Regenerative Medicine Industry Interface – a new industry collaboration in Victoria
Announcing RMI2 The Regenerative Medicine Industry Interface Regenerative Medicine An emerging field of medical science, regenerative medicine incorporates the use of cells, factors, and other biological building blocks, along with bioengineered materials and technologies for widespread clinical applications.…
Victorian medical emergency company Medical Developments International emerges as global leader
A Victorian emergency medicine company has risen to become a global leader, thanks to its range of respiratory medications. Offering new devices for asthma and chronic obstructive pulmonary disease (COPD), Medical Developments International (MDI), is turning its attention…
